Stephen L. Shiao, MD, PhD | Cedars-Sinai

Dr. Stephen Shiao, MD

Claim this profile

Cedars-Sinai Medical Center

Studies Breast Cancer
Studies Brain Tumor
12 reported clinical trials
20 drugs studied

Area of expertise

1

Breast Cancer

Stephen Shiao, MD has run 7 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV
2

Brain Tumor

Stephen Shiao, MD has run 3 trials for Brain Tumor. Some of their research focus areas include:

Stage IV

Affiliated Hospitals

Image of trial facility.

Cedars-Sinai Medical Center

Image of trial facility.

Cancer Clinical Trials Office

Clinical Trials Stephen Shiao, MD is currently running

Image of trial facility.

Cyclophosphamide After Stem Cell Transplant

for Blood Cancer

The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.

Recruiting

1 award

Phase 1

Image of trial facility.

Imaging Technique

for Atherosclerosis

The prospective single-arm pilot study, ATHERO-RT: Real-Time Atherosclerosis Activity after Thoracic Radiotherapy using Sodium Fluoride Positron Emission Tomography, will aim to: 1. To deploy first-in-kind application of fluorine 18-sodium fluoride (18F-NaF) PET (Positron Emission Tomography) /MRI (Magnetic Resonance Imaging) imaging to detect real-time atherosclerosis activity at the time of cancer diagnosis and after cardiac radiation exposure 2. To detect longitudinal changes in clonal hematopoiesis (CH) genetic architecture following thoracic RT (Radiation Therapy) in patients at high risk of cardiac dysfunction, and 3. To measure perturbations in the immune-modulatory and metabolic states following thoracic RT (Radiation Therapy) exposure in patients at high risk of cardiac dysfunction. Eligible patients will be adults (≥18 years old) with Stage II-III or oligo-metastatic stage IV malignancy (any histology) at high risk for RT-associated cardiac toxicity (defined as receiving ≥30 Gy (Gray) RT where the heart is in the treatment field54). The study will enroll a total of 10 subjects, recruited from Cedars-Sinai Medical Center. The primary endpoint will be successful completion of 18F-NaF PET imaging at the baseline and 6-month post-RT time points. Blood will be collected at baseline, end of RT, and 6-months post-RT.

Recruiting

1 award

Phase < 1

4 criteria

More about Stephen Shiao, MD

Clinical Trial Related

2 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Stephen Shiao, MD has experience with

  • Pembrolizumab
  • RT Boost
  • Neoadjuvant Stereotactic Radiosurgery
  • Neurosurgical Resection
  • Tucatinib
  • Trastuzumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Stephen Shiao, MD specialize in?

Is Stephen Shiao, MD currently recruiting for clinical trials?

Are there any treatments that Stephen Shiao, MD has studied deeply?

What is the best way to schedule an appointment with Stephen Shiao, MD?

What is the office address of Stephen Shiao, MD?

Is there any support for travel costs?